-
Something wrong with this record ?
Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia
Fedor Kryukov, Elena Dementyeva, Lenka Kubiczkova, Jiri Jarkovsky, Lucie Brozova, Jakub Petrik, Pavel Nemec, Sabina Sevcikova, Jiri Minarik, Zdena Stefanikova, Petr Kuglik, Roman Hajek
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT11154
MZ0
CEP Register
NT12130
MZ0
CEP Register
NT13190
MZ0
CEP Register
Digital library NLK
Full text - Article
Full text - Article
Full text - Article
Source
Source
Source
NLK
Free Medical Journals
from 2006 to 18 months ago
- MeSH
- Survival Analysis MeSH
- Cell Cycle genetics MeSH
- Time Factors MeSH
- Genes, cdc * MeSH
- HeLa Cells MeSH
- Cyclin-Dependent Kinase Inhibitor p16 genetics metabolism MeSH
- Middle Aged MeSH
- Humans MeSH
- Multiple Myeloma diagnosis genetics MeSH
- Tumor Cells, Cultured MeSH
- Leukemia, Plasma Cell diagnosis genetics MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Gene Expression Regulation, Neoplastic MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 ± 3.9 months for 'low' expressed and 7.5 ± 5.6 months for 'high' expressed group, p<0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 ± 3.6 months for 'low' and 8.4 ± 2.7 months for 'high' expressed group, p<0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 ± 2.8 months for 'low' and 9.8 ± 1.1 months for 'high' expressed group, p<0.0001). The overexpression of inhibitors can be explained as a compensatory reaction to growing "oncogenic stress".
Department of Clinical Hematology University Hospital Brno Czech Republic
Department of Hematology and Blood Transfusion University Hospital Bratislava Slovak Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Instituteof Clinical Hematology University Hospital Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14064120
- 003
- CZ-PrNML
- 005
- 20200219092954.0
- 007
- ta
- 008
- 140704s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ygeno.2013.06.007 $2 doi
- 035 __
- $a (PubMed)23831116
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kryukov, Fedor $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: f.kryukov@gmail.com. $7 xx0128646
- 245 10
- $a Cell cycle genes co-expression in multiple myeloma and plasma cell leukemia / $c Fedor Kryukov, Elena Dementyeva, Lenka Kubiczkova, Jiri Jarkovsky, Lucie Brozova, Jakub Petrik, Pavel Nemec, Sabina Sevcikova, Jiri Minarik, Zdena Stefanikova, Petr Kuglik, Roman Hajek
- 520 9_
- $a The objective of this study was to describe co-expression correlations of cell cycle regulatory genes in multiple myeloma (MM) and plasma cell leukemia (PCL). Our results highlight the presence of dynamic equilibrium between co-expression of activator and inhibitor gene sets. Moreover inhibitor set is more sensitive to the activator changes, not vice versa. We have shown that CDKN2A expression is associated with short-term survival in newly diagnosed MM patients (survival was 30.3 ± 3.9 months for 'low' expressed and 7.5 ± 5.6 months for 'high' expressed group, p<0.0001). Moreover low-expression CDKN2A group showed time-to-progression benefit in newly diagnosed patients (remission was 20.8 ± 3.6 months for 'low' and 8.4 ± 2.7 months for 'high' expressed group, p<0.0001) as well as in whole studied cohort of MM patients (remission was 20.8 ± 2.8 months for 'low' and 9.8 ± 1.1 months for 'high' expressed group, p<0.0001). The overexpression of inhibitors can be explained as a compensatory reaction to growing "oncogenic stress".
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a buněčný cyklus $x genetika $7 D002453
- 650 _2
- $a inhibitor p16 cyklin-dependentní kinasy $x genetika $x metabolismus $7 D019941
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a regulace genové exprese u nádorů $7 D015972
- 650 12
- $a CDC geny $7 D018816
- 650 _2
- $a HeLa buňky $7 D006367
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a plazmocelulární leukemie $x diagnóza $x genetika $7 D007952
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mnohočetný myelom $x diagnóza $x genetika $7 D009101
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a analýza přežití $7 D016019
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kryukova, Elena $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0122005
- 700 1_
- $a Bešše, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 mub2014851432
- 700 1_
- $a Jarkovský, Jiří $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 stk2008461294
- 700 1_
- $a Brožová, Lucie $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0213022
- 700 1_
- $a Petrik, Jakub $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
- 700 1_
- $a Němec, Pavel $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0162732
- 700 1_
- $a Ševčíková, Sabina, $d 1972- $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 mub2015859787
- 700 1_
- $a Minarik, Jiri $u Department of Internal medicine, Faculty of Medicine and Faculty Hospital, Palacky University, Olomouc, Czech Republic
- 700 1_
- $a Štefániková, Zdenka $u Department of Hematology and Blood Transfusion, University Hospital Bratislava, Slovak Republic $7 xx0127146
- 700 1_
- $a Kuglík, Petr, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Integrated Laboratory of Molecular Cytogenetics, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $d 1957- $7 ola2003204793
- 700 1_
- $a Hájek, Roman, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Clinical Hematology, University Hospital Brno, Czech Republic; Instituteof Clinical Hematology, University Hospital, Ostrava, Czech Republic $d 1964- $7 nlk20000083645
- 773 0_
- $w MED00001912 $t Genomics $x 1089-8646 $g Roč. 102, č. 4 (2013), s. 243-249
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23831116 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20200219093356 $b ABA008
- 999 __
- $a ok $b bmc $g 1031604 $s 862852
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 102 $c 4 $d 243-249 $i 1089-8646 $m Genomics (San Diego, Calif.) $n Genomic $x MED00001912
- GRA __
- $a NT11154 $p MZ0
- GRA __
- $a NT12130 $p MZ0
- GRA __
- $a NT13190 $p MZ0
- LZP __
- $a Pubmed-20140704